Peter Martin, M.D., associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, spoke to OncLive about future treatment approaches in the field of mantle cell lymphoma (MCL).
Over the next decade, the field will evolve significantly to include less aggressive treatment for younger patients, Martin predicts. While some patients are appropriately treated with aggressive therapy, others do not respond or are not required to receive such treatment. Clinical trials in development may help address this unmet need for younger patients, he adds.
Researchers are in the process of utilizing a new line of therapies, including Bruton’s tyrosine kinase inhibitors, PI3 kinase inhibitors, Bcl-2 inhibitors, immunomodulatory drugs, and immunotherapy agents. These therapies all have varying degrees of activity, Martin explains, adding that some of them may be even more responsive when given to patients in the frontline setting.